Search Results

19 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 47

    Identification, discussion and recommendations for the optimal generation and use of in vitro genotoxicity assay data for tobacco and nicotine products

    DESAI P.(1); CURREN R.(1); MOORE M.M.(2)
    (1) Institute for In Vitro Sciences, Gaithersburg, MD, U.S.A.; (2) Ramboll Environ Inc., Little Rock, AR, U.S.A.
    The Institute for In Vitro Sciences is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific/technical approaches for utilizing in vitro regulatory genotoxicity assay data within and across tobacco and ...
  2. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 008

    Workshop series to identify, discuss and develop recommendations for the optimal generation and use of in vitro genotoxicity assay data for tobacco and nicotine products

    MOORE M.M.(1); CURREN R.(2)
    (1) Ramboll US Corporation, Little Rock, AR, USA; (2) Institute for In Vitro Sciences, Gaithersburg, MD, USA
    The Institute for In Vitro Sciences is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific/technical approaches for utilizing in vitro regulatory genotoxicity assay data within and across tobacco and ...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 35

    Different population modeling approaches lead to directionally similar conclusions about the potential for tobacco harm reduction

    BACHAND A.(1); SULSKY S.(1); CURTIN G.(2)
    (1) Ramboll U.S. Corp., Amherst, MA, U.S.A.; (2) RAI Services Co., Winston-Salem, NC, U.S.A.
    There are a number of dynamic population models that can be used to quantify the overall population health effects of beneficial and/or harmful changes in tobacco use patterns. These models can be broadly categorized as either following a single birth ...
  4. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 36 (also presented at TSRC 2018)

    Multi-dimensional tipping point analyses: Assessing simultaneous shifts in tobacco use patterns from a higher to a lower risk product

    BACHAND A.(1); SULSKY S.(1); CURTIN G.(2)
    (1) Ramboll U.S. Corp., Amherst, MA, U.S.A.; (2) RAI Services Co., Winston-Salem, NC, U.S.A.
    The Dynamic Population Modeler (DPM(+1)) employs a birth cohort framework to estimate effects on population mortality if tobacco use patterns shift from a higher- to lower-risk product. DPM(+1) allows for evaluation of changes in use patterns within the ...
  5. TSRC, Tob. Sci. Res. Conf., 2018, 72, abstr. 037 (also presented at CORESTA 2018)

    Multi-dimensional tipping point analyses: assessing simultaneous shifts in tobacco use patterns from a higher to a lower risk product

    CURTIN G.M.(1); BACHAND A.(2); SULSKY S.(2)
    (1) RAI Services Company, Winston-Salem, NC, USA; (2) Ramboll US Corporation, Amherst, MA, USA
    The Dynamic Population Modeler (DPM(+1)) employs a birth cohort framework to estimate effects on population mortality if tobacco use patterns shift from a higher- to lower-risk product. DPM(+1) allows for evaluation of changes in use patterns within the ...
  6. TSRC, Tob. Sci. Res. Conf., 2018, 72, abstr. 076

    Do levels of menthol in mainstream cigarette smoke influence dependence? Data from NHANES 2007-2014

    PARMS T.(1); VAN LANDINGHAM C.(2); MARANO K.M.(1)
    (1) RAI Services Company, Winston-Salem, NC, USA; (2) Ramboll, Monroe, LA, USA
    A 2013 preliminary scientific evaluation by the U.S. Food and Drug Administration (FDA) concluded that menthol in cigarettes is likely associated with increased initiation and progression to regular cigarette smoking, increased dependence, and reduced ...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 38

    Assessing the likelihood and magnitude of a population health benefit following market introduction of a modified risk tobacco product (MRTP)

    CURTIN G.(1); SULSKY S.(2); BACHAND A.(2)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ US Corp., Amherst, MA, U.S.A.
    The evaluation and implementation of tobacco policies intended to reduce harm to the population as a whole, including tobacco users and non-users, must assess the potential for both intended and unintended consequences associated with those policies. ...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 39

    Addressing U.S. FDA’s population health standard for Camel Snus with modified risk messaging

    CURTIN G.(1); BACHAND A.(2); SULSKY S.(2); GERLACH K.(3); PILLITTERI J.(4); SHIFFMAN S.(3)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ US Corp., Amherst, MA, U.S.A.; (3) Pinney Associates, Inc., Pittsburgh, PA, U.S.A.; (4) Pinney Associates, Inc., Burlington, VT, U.S.A.
    R.J. Reynolds Tobacco Company has submitted Modified Risk Tobacco Product applications to the U.S. Food and Drug Administration seeking risk modification orders for Camel Snus advertising, which includes information that smokers who switch completely to ...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 40

    FDA’s proposed NNN product standard: review of the scientific evidence

    MARANO K.M.(1); BACHAND A.(2); LIU C.(1); SULSKY S.(2); MARIANO G.(2); CURTIN G.M.(1); PARMS T.(1); GREEN T.(3); GENTRY P.R.(3)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ US Corp., Amherst, MA, U.S.A.; (3) Ramboll Environ, Monroe, LA, U.S.A.
    The U.S. Food and Drug Administration (FDA) has published a proposed standard of 1 µg/g (dry weight) N-nitrosonornicotine (NNN) in finished smokeless tobacco products. FDA’s rationale for the standard is that NNN is a potent carcinogen, NNN is a major ...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 37

    FDA’s proposed NNN product standard: quantitative risk assessment

    MARANO K.M.(1); GENTRY P.R.(2); LIU C.(1)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ, Monroe, LA, U.S.A.
    The U.S. Food and Drug Administration (FDA) has published a proposed standard for N-nitrosonornicotine (NNN) content in finished smokeless tobacco products. The proposed NNN limit of 1 part per million (ppm) dry weight was derived based on a target excess ...